CC
RXRX icon

Casdin Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Casdin Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$508K Hold
165,323
– – 0.04% 38
2025
Q4 		$676K Hold
165,323
– – 0.04% 36
2025
Q3 		$807K Hold
165,323
– – 0.07% 28
2025
Q2 		$837K Hold
165,323
– – 0.08% 28
2025
Q1 		$875K Hold
165,323
– – 0.07% 38
2024
Q4 		$1.12M Buy
+165,323
New +$1.11M 0.07% 35
2022
Q2 		– Sell
-548,156
Closed -$3.92M – 47
2022
Q1 		$3.92M Hold
548,156
– – 0.18% 44
2021
Q4 		$9.39M Hold
548,156
– – 0.26% 45
2021
Q3 		$12.6M Hold
548,156
– – 0.31% 42
2021
Q2 		$20M Buy
+548,156
New +$16.2M 0.51% 37

Other funds holding RXRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return